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Abstract 
Alexander disease (AxD) is a genetic leukodystrophy caused by GFAP mutations leading to astrocyte 
dysfunction. Neonatal AxD is a rare phenotype with onset in the first month of life. The proband, 
belonging to a large pedigree with dominantly inherited benign familial neonatal epilepsy (BFNE), 
had a phenotype distinct from the rest of the family, with hypotonia and macrocephaly in addition to 
drug-resistant neonatal seizures. The patient deteriorated and passed away at 6 weeks of age. The 
pathological and neuroimaging data were consistent with the diagnosis of AxD. Genetic analysis of 
the proband identified a novel de novo GFAP missense mutation and a KCNQ2 splice site mutation 
segregating with the BFNE phenotype in the family. The GFAP mutation was located in the coil 2B 
region of GFAP protein, similar to most neonatal-onset AxD cases with an early death. The clinical 
and neuroradiological features of the previously published neonatal AxD patients are presented. This 
study further supports the classification of neonatal-onset Alexander disease as a distinct phenotype 
based on the age of onset.  
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Introduction  
Alexander disease (AxD; MIM 203450) is a rare leukodystrophy typically caused by heterozygous 
point mutations in GFAP (MIM 137780) encoding glial fibrillary acidic protein (GFAP).1,2 The 
mutant GFAP disrupts the normal intermediate filament network formation causing astrocyte 
dysfunction, reviewed in3. Abnormal astrocytic accumulations of intracytoplasmic proteinaceous 
inclusions, Rosenthal fibres, are characteristic of AxD. Three age-dependent clinical subtypes — 
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infantile, juvenile and adult — have been recognized.2,4 The infantile subtype is the most common 
form manifesting with seizures, developmental delay, pyramidal tract signs and progressive 
macrocephaly4-5 Only 17 patients with neonatal-onset AxD have been reported earlier (Table 1)2,6-12, 
showing hypotonia and failure to thrive preceding drug-resistant seizures and macrocephaly.9,13 
Neuroradiologically, extensive periventricular enhancement and white matter abnormalities of frontal 
predominance have been described, with involvement of the basal ganglia and cerebellum.10,14 The 
radiological changes can be noted already in utero.7 
Mutations in KCNQ2 (MIM 602235) causing impairment of the voltage-gated potassium channel 
Kv7.2 lead to a wide range of epileptic phenotypes, including benign familial neonatal epilepsy 
(BFNE, or benign familial neonatal seizures, BFNS, MIM 121200), typically caused by autosomal 
dominant mutations. BFNE manifests with high frequency of seizures in the first days or weeks of 
life, and spontaneous remission by 6 months of age.15,16  
We describe a patient with severe AxD of neonatal-onset, a member of a pedigree with 15 individuals 
affected with BFNE.  The clinical and neuroradiological features of the published cases of neonatal 
AxD are reviewed. 
 
Clinical report 
The proband was a member of a Finnish family with history of neonatal seizures (unpublished, data 
not shown). He was born at 38 weeks of gestation by uncomplicated vaginal delivery. The Apgar 
scores were 5/7/7, weight 3.55 kg, height 51 cm and head circumference 37.5 cm. Drug-resistant 
seizures started on the fourth day of life. He did not benefit from phenobarbital, levetiracetam, 
topiramate or pyridoxine. The electroencephalogram (EEG) developed to burst suppression pattern 
by three weeks of age.  The head circumference surpassed the 95th percentile at four weeks of life. 
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He became lethargic with prolonged seizures and passed away at the age of six weeks. Extensive 
metabolic screening was normal. 
The study was approved by the Regional Ethics Committee of the Northern Ostrobothnia Hospital 
District and Helsinki University Hospital.  The guidelines of the Helsinki Declaration were followed 
(World Medical Association 1964). A written informed consent was obtained from the parents of the 
proband and the other study subjects or their parents. 
 
Radiological investigations 
Brain ultrasound was initially normal but the third and lateral ventricles dilated at two weeks of age 
(Fig. 1, Panel A). At the age of three weeks, magnetic resonance imaging (MRI) suggested white 
matter loss and hydrocephalus, caused by aqueductal stenosis due to enlargement of the tectum, and 
showed extensive signal abnormalities (Fig. 1, Panel B).  
  
Genetic investigations 
The proband’s DNA was extracted from peripheral blood sample. The entire coding region and the 
highly conserved exon-intron splice junctions of GFAP were analyzed from genomic DNA by 
sequencing in an accredited clinical laboratory. Reference sequences were NM_001242376.1, 
NM_001131019.2, and NM_002055.4. Pathogenicity of the found mutation was assessed using 
Condel and PON-P2 prediction tools.17,18 A de novo heterozygous NM_001242376.1:c.1106T>C; 
p.(Leu369Pro) variant located in the coil 2B area of GFAP was identified. It affects a highly 
conserved amino acid with in silico predictions suggesting a pathogenic effect (the Condel consensus 
deleteriousness score of missense mutations: 0.729 (0=neutral, 1=deleterious) and the PON-P2 
probability for pathogenicity: 0.959). The variant has not been previously described and it is classified 
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as likely pathogenic.19,20 The patient’s DNA was also sequenced for the novel 
NG_009004.2(NM_172107.3):c.387+2del variant affecting the splice donor site of intron 2 of 
KCNQ2, previously identified to segregate with the BFNE phenotype in the family (unpublished, data 
not shown). The variant putatively affects splicing of KCNQ2 and is classified as pathogenic.19  
 
Pathological investigations 
At autopsy, the head was macrocephalic with a prominent forehead. The cerebral cortices, basal 
ganglia and hippocampi were symmetrically deformed. White matter was scarce and cyanotic. Lateral 
ventricles were dilated. Eosinophilic intracytoplasmic inclusions were most prominently present in 
periventricular and subpial astrocytes (Fig. 2). These inclusions were immunoreactive for GFAP and 
αB-crystallin consistent with the diagnosis of AxD. Rosenthal fibers were scarce. Periventricular 
histopathological changes correlate with the periventricular rims seen on MRI.  
 
Discussion 
Few patients with neonatal-onset AxD have been described earlier (Tables 1 & 2). We present a 
neonate with a novel pathogenic mutation in GFAP. Histopathology demonstrated GFAP and αB-
crystallin positive astrocytic inclusions consistent with previous reports of AxD (Fig. 2). 
Characteristic Rosenthal fibers and white matter signal abnormalities were not prominently present, 
which has been suggested to be a feature of AxD patients with very early onset.9 Among the neonatal 
AxD cases described earlier, the diagnostic MRI criteria developed by van der Knaap were not 
fulfilled in 6/17 (35%) patients (Table 2).14 However, all six had AxD confirmed by histopathology 
or DNA testing. 
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The proband presented typical findings of neonatal AxD as defined by Springer et al. and fulfills 4/5 
diagnostic MRI criteria.9 These include white matter abnormalities with frontal predominance, 
presence of a periventricular rim of decreased signal intensity on T2-weighted images and increased 
signal intensity on T1-weighted images, and involvement of the basal ganglia, thalami and 
cerebellum. The fifth criterion, contrast enhancement of the lesions, could not be assessed because 
the proband’s young age precluded the use of contrast media. Enlarged tectum, a rarely reported 
feature, was noticed.8 In infantile AxD, typical MRI shows abnormal signal intensity of the frontal 
white matter in a symmetrical distribution. MRI of the proband had only slight changes in the white 
matter frontally. It may be difficult to distinguish unmyelinated white matter from abnormal white 
matter that may only be seen as slight hyperintensity on T2- and hypointensity on T1-weighted 
images.14 
Canavan disease and Leigh syndrome were considered in the differential diagnosis. Similar to AxD, 
the thalamus and globus pallidus are typically involved in Canavan disease while the putamen and 
caudate nucleus are spared, and extensive cerebral white matter changes have no frontal 
predominance.21 The white matter and basal ganglia changes may sometimes mimic mitochondrial 
disorders. Symmetrical signal abnormalities of the basal ganglia, midbrain, and periventricular white 
matter with frontal predominance have been reported in Leigh syndrome but the periventricular rim 
of white matter characteristic for AxD may be spared.22  
The course of the disease in the current case was rapidly progressive leading to death at the age of six 
weeks, which is earlier than described (Table 1 and 2).2,6-12 Previous studies have associated the 
earlier presentation of symptoms with more severe disease progression, and a correlation between 
genotype and disease severity has been described.5,12 The mutation reported here affects a highly 
conserved amino acid residue located in the coil 2B region of GFAP, where mutations causing 
neonatal-onset phenotype and especially an earlier death are predominantly situated (Fig. 3, Table 1). 
This suggests that mutations in the coil 2B domain are more intolerable than mutations affecting other 
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domains. The KCNQ2 mutation, which alone was sufficient to cause neonatal seizures in the family, 
was most likely irrelevant for the disease course in the current case. 
This study gives further support for the neonatal AxD as a distinct disease type based on the age of 
onset, and adds to the clinical and radiological phenotype of this severe disease.  
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Figure captions 
 
Fig. 1. Neuroimaging of the proband.  
Panel A: Coronal brain ultrasound images, ages one (A), two (B), three (C) and 4.5 weeks (D), 
showed progressive enlargement of the lateral (arrow) and third (arrowhead) ventricles. Panel B: 
Brain MRI at the age of three weeks. T1-(A‒D) and T2-weighted (E‒H) images show characteristic 
findings of Alexander disease. T1-weighted images demonstrate a hyperintense periventricular rim 
(A and B, long arrows) and deep frontal white matter densities (C, short arrows). The basal ganglia 
are swollen and hyperintense (A, short arrows) and thalami are mildly T1-hyperintense (A, small 
arrowheads). The third and lateral ventricles are enlarged (A, B, D, E). The swollen, T2-hyperintense 
tectum compresses aqueduct of Sylvius (D, E and H, big arrowhead). The optic chiasm is 
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hyperintense (D, small arrowhead). The fornix is thickened and hyperintense (A, big arrowhead). The 
hilum of dentate nucleus of the cerebellum is T1- and T2-hyperintense (B and F, short arrows). Pons 
(F, long arrows) and medulla (G and H, long arrow) are T2-hyperintense. 
 
Fig. 2. Histopathology of the cerebral cortex from the autopsy sample of the patient with 
neonatal Alexander disease. 
Hematoxylin and eosin stain of the cerebral cortex (A) demonstrates eosinophilic cytoplasmic 
inclusions in subpial astrocytes. Immunohistochemically the material is glial fibrillary acidic protein 
(GFAP, B) and αB-crystallin (C) positive, which is characteristic of Alexander disease. 
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Fig. 3 Protein structure of glial fibrillary acidic protein and distribution of mutations in 
Alexander disease (AxD).  
The α-helical domains (grey boxes) are connected by nonhelical linker regions (white boxes). 
Numbers indicate the altered amino acid locations. The published mutations (circles) in neonatal AxD 
are shown above the protein. For reference, other forms of AxD reported by Li et al.2 are shown 
below, except for the neonatal cases that are above marked with an asterisk. The current case is 
marked with an arrow. 
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Table 1. Reported cases of neonatal Alexander disease. 
Reference case mutation Death 
   DNA amino acid protein structure  
current case 1106 T>C Leu369Pro Coil 2B  1.5 months 
Springer et al.9 patient no. 1 n/a n/a n/a  6 months 
Springer et al.9 patient no. 2 n/a n/a n/a  20 months 
Springer et al.9 patient no. 3 n/a n/a n/a  5 years 
van der Knaap et al.10 patient no. 8 758 C>G Ala253Gly Linker 2  Alive 7 years 
van der Knaap et al.10 patient no. 10 343 G>A Val115Ile Linker 1  8 months 
Vazquez et al.7 n/a Met73Thr Coil 1A  n/a 
Li et al.2 patient no. 3 226 C>T Leu76Phe Coil 1A  9 years 
Li et al.2 patient no. 10 290 T>C Leu97Pro Coil 1A  6 years 5 months 
Li et al.2 patient no. 21 715 C>T Arg239Cys Coil 2A  2 years 5 months 
Li et al.2 patient no. 32 
 
379 HL Ins Coil 2B  3.5 months 
Li et al.2,11 patient no. 33 1055 T>C Leu352Pro Coil 2B  38 days 
Li et al.2 patient no. 35 1090 G>C Ala364Pro Coil 2B  4 months 
Li et al.2 patient no. 36 1096 T>C Tyr366His Coil 2B  1.5 years 
Rodriquez et al.12 patient no. 3 250 G>A Arg79His Coil 1A  Alive 7.5 years 
Rodriquez et al.12 patient no. 8 276 C>T Arg88Cys Coil 1A  Alive 2.5 years 
Rodriquez et al.12 patient no. 9 276 C>A Arg88Ser Coil 1A  Alive 3.5 years 
Meins et al.6 patient no. 4 304 T>C Leu97Pro Coil 1A  Alive 6 years 
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Table 2. Clinical characteristics of the published cases of neonatal Alexander disease. 
 
Number of cases 
with variable 
adequately 
reported 
Sex 10 males/14 
Death median 12 mo  
Death <2 years 8/13 
Hydrocephalus 5/5 
Macrocephaly 11/18 
Raised ICP 5/5 
Retardation or regression 13/14 
Hypotonia 5/5 
Spasticity 4/14 
Seizures 12/17 
Ataxia 2/9 
Hyperreflexia 1/1 
Elevated CSF protein 3/3 
WM abnormality 11/12 
Frontal WM abnormality 10/11 
Basal ganglia abnormality 8/9 
Enlarged ventricles 7/8 
Periventricular rim, T1-
hyper- and T2-hypointense 
7/8 
Brainstem lesions 3/5 
Contrast enhancement 6/6 
GFAP inclusions 7/7 
Rosenthal fibers 5/7 
Abbreviations: ICP = intracranial pressure, CSF 
= cerebrospinal floud, GFAP = glial fibrillary 
acidic protein, WM = white matter 
 
